Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!
Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Pushkar Shinde Article rating: 5.0

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Sensex Dips While Mid & Small-Caps Shine Bright!
Sensex Dips While Mid & Small-Caps Shine Bright!

Sensex Dips While Mid & Small-Caps Shine Bright!

Nifty 50 Slips, But Broader Markets Lead the Charge; Consumer Durables and Pharma Sectors Outperform

Pushkar Shinde Article rating: No rating

Nifty 50 Slips, But Broader Markets Lead the Charge; Consumer Durables and Pharma Sectors Outperform 

Exciting developments in the pharma industry that could skyrocket your portfolio; have a look
Exciting developments in the pharma industry that could skyrocket your portfolio; have a look

Exciting developments in the pharma industry that could skyrocket your portfolio; have a look

Previously revolutionising the IT industry, these technological advancements are currently enhancing efficiency, productivity and cost control in the pharmaceutical industry

Mandar Wagh Article rating: 4.3

Previously revolutionising the IT industry, these technological advancements are currently enhancing efficiency, productivity and cost control in the pharmaceutical industry

Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!
Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!

Don’t miss the action in this pharmaceutical stock: The Cup and handle pattern breakout is seen with huge volumes!

Notably, the RSI has entered a super bullish territory, indicating a significant shift in momentum.

Karan Dsij Article rating: 4.7

The Nifty Pharmaceutical index has surged by an impressive 30 per cent on a year-to-date basis in 2023, significantly outperforming the Nifty 50 index. Against the backdrop of India experiencing a single-day spike of 628 new COVID-19 cases

Upcoming collaboration: Two leading pharma company stocks to watch out for
Upcoming collaboration: Two leading pharma company stocks to watch out for

Upcoming collaboration: Two leading pharma company stocks to watch out for

US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns

Kiran Shroff Article rating: 4.5

Upcoming collaboration: Two leading pharma company stocks to watch out for                                                                                                                                                                                            US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns.

NSE revises circuit limit of two stocks, one of them hit a fresh 52-week high today; do you own it?
NSE revises circuit limit of two stocks, one of them hit a fresh 52-week high today; do you own it?

NSE revises circuit limit of two stocks, one of them hit a fresh 52-week high today; do you own it?

The stock was among the top gainers list on Wednesday as the stock jumped more than 14.5 per cent

Karan Dsij Article rating: 3.9

On National Stock Exchange (NSE) has revised the circuit limit of two stocks. Out of two stocks, one stock has seen circuit limit being narrowed while for the other one, circuit filter got widened.

RSS
12

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR